{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:46:12Z","timestamp":1793245572994,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s11926-013-0398-z","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T07:28:15Z","timestamp":1389252495000},"source":"Crossref","is-referenced-by-count":58,"title":["Anti-Interleukin-1 Therapy in the Management of Gout"],"prefix":"10.1007","volume":"16","author":[{"given":"Naomi","family":"Schlesinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"398_CR1","doi-asserted-by":"crossref","unstructured":"\u2022 Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008. Arthritis Rheum. 2011;63(10):3136\u201341. This is an excellent paper addressing incidence of frequency of gout in the USA.","DOI":"10.1002\/art.30520"},{"key":"398_CR2","doi-asserted-by":"crossref","unstructured":"\u2022 Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155\u201363. This is an excellent paper addressing much needed information about comorbidities in gout and how they affect prescriptions.","DOI":"10.1016\/j.amjmed.2010.09.012"},{"key":"398_CR3","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1172\/JCI28075","volume":"116","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Shi Y, Hearn A, Fitzgerald K, Golenbock D, Reed G, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest. 2006;116:2262\u201371.","journal-title":"J Clin Invest"},{"key":"398_CR4","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.4049\/jimmunol.138.10.3213","volume":"138","author":"FS Giovine Di","year":"1987","unstructured":"Di Giovine FS, Malawista SE, Nuki G, Duff GW. Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal- induced IL-1. J Immunol. 1987;138:3213\u20138.","journal-title":"J Immunol"},{"key":"398_CR5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237\u201341.","journal-title":"Nature"},{"issue":"Suppl 1","key":"398_CR6","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar1908","volume":"8","author":"RN Cronstein","year":"2006","unstructured":"Cronstein RN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther. 2006;8 Suppl 1:S3.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"398_CR7","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","volume":"9","author":"A So","year":"2007","unstructured":"So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.","journal-title":"Arthritis Res Ther"},{"issue":"9, Supplement","key":"398_CR8","first-page":"S163","volume":"60","author":"M Cho","year":"2010","unstructured":"Cho M, Ghosh P, Hans G, Rhiannon J, Gardner GC, Simkin PA. The safety and efficacy of anakinra in the treatment of acute gout in hospitalized patients. Arthritis Rheum. 2010;60(9, Supplement):S163.","journal-title":"Arthritis Rheum"},{"key":"398_CR9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.semarthrit.2010.03.001","volume":"40","author":"K Chen","year":"2010","unstructured":"Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum. 2010;40:210\u20134.","journal-title":"Semin Arthritis Rheum"},{"key":"398_CR10","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/ar4303","volume":"15","author":"S Ottaviani","year":"2013","unstructured":"Ottaviani S, Molt\u00f2 A, Ea H-K, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15:R123.","journal-title":"Arthritis Res Ther"},{"key":"398_CR11","unstructured":"properties http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails ."},{"issue":"3","key":"398_CR12","first-page":"138","volume":"34","author":"S Kapur","year":"2009","unstructured":"Kapur S, Bonk ME. Rilonacept (Arcalyst), an Interleukin-1 Trap for the Treatment of Cryopyrin-Associated Periodic Syndromes. P T. 2009;34(3):138\u201341.","journal-title":"P T"},{"issue":"1","key":"398_CR13","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/ar4159","volume":"15","author":"RA Terkeltaub","year":"2013","unstructured":"Terkeltaub RA, Schumacher HR, Carter JD, Baraf HSB, Evans RR, Wang J, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther. 2013;15(1):R25.","journal-title":"Arthritis Res Ther"},{"key":"398_CR14","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","volume":"68","author":"R Terkeltaub","year":"2009","unstructured":"Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in the treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009;68:1613\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"398_CR15","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/rheumatology\/ket114","volume":"52","author":"E Mitha","year":"2013","unstructured":"Mitha E, Schumacher HR, Fouche L, Luo SF, Weinstein SP, Yancopoulos GD, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology. 2013;52(7):1285\u201392.","journal-title":"Rheumatology"},{"key":"398_CR16","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Schumacher HR, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, et al. Rilonacept (IL-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase 2 clinical trial. Arthritis Rheum. 2012;64(3):876\u201384. An important study demonstrating the use of IL-1 blockade in gout prophylaxis.","DOI":"10.1002\/art.33412"},{"issue":"10","key":"398_CR17","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","volume":"62","author":"A So","year":"2010","unstructured":"So A, De Meulemeester M, Pikhlak A, Y\u00fccel AE, Richard D, Murphy V, et al. Canakinumab for treatment of acute flares in refractory gouty arthritis. Arthritis Rheum. 2010;62(10):3064\u201374. PA.","journal-title":"Arthritis Rheum"},{"key":"398_CR18","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","volume":"13","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger N, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther. 2011;13:R53.","journal-title":"Arthritis Res Ther"},{"key":"398_CR19","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol therapy: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264\u201371. An important study demonstrating the use of IL-1 blockade in gout prophylaxis.","DOI":"10.1136\/ard.2010.144063"},{"key":"398_CR20","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","volume":"71","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger N, Alten R, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their extensions. Ann Rheum Dis. 2012;71:1839\u201348.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"398_CR21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1699-258X(07)73613-6","volume":"3","author":"J Mata Llord de La","year":"2007","unstructured":"de La Mata Llord J, Gonzalez Crespo R, Maese Manzano J. Treatment of rheumatoid arthritis with anakinra: a systematic review. Reumatol Clin. 2007;3(4):153\u20138.","journal-title":"Reumatol Clin"},{"key":"398_CR22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68:25\u201332.","journal-title":"Ann Rheum Dis"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-013-0398-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-013-0398-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-013-0398-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T15:42:23Z","timestamp":1688917343000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-013-0398-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,10]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["398"],"URL":"https:\/\/doi.org\/10.1007\/s11926-013-0398-z","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,10]]},"article-number":"398"}}